Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | PLAT | P00750 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054382 | 1.00 | CYP19A1 (1.00) | CYP19A1NPC1MEN1KMT2APOLB | |
| SCHEMBL7514925 | 0.90 | CYP19A1 (0.82) | CYP19A1NPC1MEN1KMT2APOLB | |
| SCHEMBL2244487 | 0.88 | CYP19A1 (0.78) | CYP19A1NPC1MEN1KMT2APOLB | |
| SCHEMBL1673078 | 0.87 | CYP19A1 (0.76) | CYP19A1NPC1MEN1KMT2APOLB | |
| SCHEMBL14694251 | 0.85 | CYP19A1 (0.74) | CYP19A1NPC1MEN1KMT2APOLB | |
| SCHEMBL18180609 | 0.85 | CYP19A1 (0.74) | CYP19A1NPC1MEN1KMT2APOLB | |
| SCHEMBL19739173 | 0.85 | CYP19A1 (0.74) | CYP19A1NPC1MEN1KMT2APOLB | |
| SCHEMBL7133332 | 0.85 | CYP19A1 (0.74) | CYP19A1NPC1MEN1KMT2APOLB | |
| SCHEMBL18160165 | 0.85 | CYP19A1 (0.74) | CYP19A1NPC1MEN1KMT2APOLB | |
| SCHEMBL18770069 | 0.84 | CYP19A1 (0.72) | CYP19A1NPC1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-12377079-B2 | Antibacterial compounds and uses thereof | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2025-08-05 | — | — | US | disclosed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-12263159-B2 | Fused ring compound having urea structure | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240285597-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4373883-A1 | COMPOUND, RUBBER BLEND CONTAINING THE COMPOUND, VEHICLE TIRE COMPRISING THE RUBBER BLEND IN AT LEAST ONE COMPONENT, PROCESS FOR PRODUCING THE COMPOUND, AND USE OF THE COMPOUND AS AN AGEING PROTECTANT AND/OR ANTIOZONANT AND/OR DYE | Continental Reifen Deutschland GmbH (DE) | 2024-05-29 | — | — | EP | disclosed |
| CN-112654608-B | Fused ring compound having urea structure | 桑福德伯纳姆普利斯医学发现研究所 | 2024-05-07 | — | — | CN | disclosed |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2024-03-21 | — | — | US | disclosed |
| CN-117677657-A | Compound, rubber blend comprising the compound, vehicle tyre comprising the rubber blend in at least one component, method for producing the compound and use of the compound as an ageing protectant and/or antiozonant and/or dye | 大陆轮胎德国有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11918568-B2 | Fused ring compound having urea structure | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2007117715-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117715-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
| EP-1501810-A1 | IONIC LIQUIDS | Bayer MaterialScience AG (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093246-A1 | IONIC LIQUIDS | BAYER MATERIALSCIENCE AG (DE) | 2003-11-13 | — | — | WO | disclosed |
| US-20030204041-A1 | Ionic liquids | BAYER AKTIENGESELLSHAFT (DE) | 2003-10-30 | — | — | US | disclosed |
| US-5223510-A | ALKYLAMINOALKYL DERIVATIVES OF BENZOFURAN, BENZOTHIOPHENE, INDOLE AND INDOLIZINE, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1993-06-29 | — | — | US | disclosed |
| US-4118561-A | ANTIBACTERIAL, SYNERGISTIC, ANTI-CANCER ACTIVITY, ANTI-FOLIC ACID ACTIVITY | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12263159-B2 | Fused ring compound having urea structure | NAMPT, NME4, NDUFAB1 | CYP19A1 3380/4885NPC1 869/4885MEN1 1161/4885 |
| US-11918568-B2 | Fused ring compound having urea structure | NAMPT, NME4, ABAT | CYP19A1 3533/4885NPC1 973/4885MEN1 1414/4885 |
| US-20240285597-A1 | FUSED RING COMPOUND HAVING UREA STRUCTURE | NAMPT, NME4, NDUFAB1 | CYP19A1 3380/4885NPC1 869/4885MEN1 1161/4885 |
| US-12377079-B2 | Antibacterial compounds and uses thereof | CLPP, SPOUT1, MRPL21 | CYP19A1 4066/4885NPC1 1188/4885MEN1 3865/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | CYP19A1 273/4885NPC1 4082/4885MEN1 3366/4885 |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | CYP19A1 4298/4885NPC1 38/4885MEN1 4687/4885 |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | CFTR, ABCD3, ABCC2 | CYP19A1 2885/4885NPC1 18/4885MEN1 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.